Nova Law Review
Volume 26, Issue 2

2002

Article 2

Introduction: Health Care in the 21st Century:
Cost, Quality, and Access in the New
Millennium
Kathy L. Cerminara∗

∗

Copyright c 2002 by the authors. Nova Law Review is produced by The Berkeley Electronic
Press (bepress). https://nsuworks.nova.edu/nlr

Cerminara: Introduction: Health Care in the 21st Century: Cost, Quality, and

Introduction: Health Care in the 21st Century: Cost,
Quality, and Access in the New Millennium
Kathy 1. Cerminara*

Everyone requires health care at some point during his or her lifetime,
and the law increasingly regulates the cost, quality, and access to such health
care. Through the 2001 Goodwin Seminar, Nova Southeastern University's
Shepard Broad Law Center examined health care in the twenty-first century
by adopting an interdisciplinary approach, focusing on concerns about cost,
quality, and access as the linchpins of health care policy, and considering the
future of health care in the United States and internationally. I am proud to
have created and taught the seminar, memorialized in this special issue of the
Nova Law Review.

The seminar's focus on health care policy was particularly timely
during the Winter term of 2001 and continues to be timely as this issue
appears. As the seminar proceeded, the news media reported debates about
the use of human embryonic stem cells in medical research,' an issue raising
continuing moral, ethical, legal, and medical quandaries. 2 Reports of numerous incidences of medical error had recently surfaced,3 leaving one to
wonder and to continue wondering, about the basic level of problems that
remain in the health care system, even as medical advances magnify the level
of sophistication and expertise Americans expect in health care. As Americans hear of and expect to receive more and more technologically advanced
medical treatment, policymakers struggle to facilitate appropriate access to
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1.
See, e.g., Washington in Brief, WASH. POST, Mar. 7, 2001, at A4.
2.
Compare Elliott Abrams et al., On Human Embryos and Medical Research: An
Appeal for Ethically Responsible Science and Public Policy, 16 ISSUES L & MED. 261 (2001)
(arguing against human embryonic stem cell research on moral grounds), with Ronald M.
Green, Stopping Embryo Research, 9 HEALTH MATRIX 235, 252 (1999) (terming opposition to
human embryonic research "research obstruction").
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such treatment, control costs, and assure quality of treatment.4 The decisions
of those policymakers affect not only the United States but also the international medical community, for legal decisions governing health care policy
in the United States can and do affect access to medicines and medical care
in other countries.
In this issue of the Nova Law Review, the reader will find articles by
four distinguished visiting professors, each addressing issues arising within
his or her special sphere of expertise within the larger topic of health care
policy. Ranging from a former secretary of the Department of Health and
Human Services, to an epidemiologist with an international human rights
organization, a former presidential advisor, and an expert in bioethics, these
authors permit the reader to explore the full realm of policy issues confounding those attempting to improve health care.
For example, the Honorable Louis W. Sullivan, M.D. served as Secretary of Health and Human Services from March 10, 1989 through the end of
President George H.W. Bush's administration. Now president of Morehouse
School of Medicine in Atlanta, Dr. Sullivan writes about health disparities in
the United States, 6 explaining that there exists severe and continuing disparities in the level of health care provided to and the health enjoyed by minorities as compared with Caucasians.
In 1993, hoping to resolve some of those health disparities as well as to
equalize access to health care and coverage across the United States, President Bill Clinton proposed a comprehensive National Health Security Plan in
an attempt to restructure the health care system.7 Goodwin Distinguished
Visiting Professor, Christopher C. Jennings, served as Senior Health Policy
4.
See generally Peter D. Jacobson, Regulating Health Care: From Self-Regulation
to Self-Regulation?, 26 J. HEALTH POL., POL'Y & L. 1165 (2001) (part of a special issue

discussing health care policy since and in light of the influential article, Kenneth J. Arrow,
Uncertaintyand the Welfare Economics of Medical Care, 53 AM. ECON. REv. 941 (1963)).

5.
One example is the extent to which patent laws protect brand-name drugs. The
availability of generic drugs greatly affects the prices manufacturers of brand-name drugs can
charge for their products in both the United States and other countries. See generally S. Van
McCrary & Cheryl J.C. Erwin, Thinking Globally About Biotech Ethics: Is the Law Enough?,

666 PRAC. L. INST./PAT. 983, 1008-09 (2001) (noting this struggle relating to availability of
AIDS drugs in developing countries). Recent inroads on patent protections have encouraged
generic drug makers in their economic battle against brand-name drug manufacturers. See,
e.g., Glenn Singer, Makers of Generics Get Boosts in Courts, Capitol, SUN-SENTINEL (Ft.
Lauderdale), Jan. 15, 2002, at DI.
6.
Louis W. Sullivan, A Conversation with Dr. Louis Sullivan, 26 NOVA L. REV. 467
(2002).
7.
See THE PRESIDENT'S HEALTH SECURITY PLAN (1993).
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Advisor and Deputy Assistant to the President under President Clinton. As
such, working out of the President's Domestic Policy Council and in conjunction with the National Economic Council, Mr. Jennings was charged
with developing the Administration's health care policy and played a lead
role in the drama surrounding the President's proposal and its subsequent
failure in Congress. Here, Mr. Jennings, from the perspective of someone
who has tried but whose efforts fell prey to the political process, discusses
steps that must be taken and issues that must be addressed to improve the
American health system.8
Many of the steps the United States may choose to take are governed,
not only by economic and political considerations, but also by moral and
ethical judgments. Medical research on human tissue, for example, holds
great promise for bettering the health care system by leading to cures or
treatments for a variety of diseases. Yet, the question arises as to how the
law should regulate such research, especially in light of ethical and moral
questions surrounding its use. R. Alta Charo is Professor of Law and Medical Ethics at the University of Wisconsin at Madison, where she is on the
faculty of the Law School and the Medical School's Program in Medical
Ethics. A former member of President Clinton's National Bioethics Advisory Commission, Professor Charo has considered the role that ethical and
moral judgments play in health care policymaking. Her essay addresses
legal issues arising from the use of human tissue and concludes that "[a]
more robust form of national control over the market in human tissue... will probably depend upon resolution of political and legal views of
the body." 9
Finally, the United States should not forget that, given today's global
economy, any decisions made with regard to health care policy inevitably
will affect other nations in some way. United States regulation of the production of pharmaceuticals, for example, often impacts the drugs that are
available and the prices at which they are available in other countries. AnneValerie Kaninda, M.D., a medical advisor and epidemiologist with Doctors
Without Borders/M~decins Sans Fronti~res, writes of the interrelationship
between pharmaceutical production, its regulation, intellectual property

8.

Christopher C. Jennings, A Conversation with ChristopherC. Jennings, 26 NOVA

L. REv. 403 (2002).
9.
R. Alta Charo, Skin and Bones: Post-Mortem Markets in Human Tissue, 26
NovA L. REv. 421, 450 (2002). See generally Henry T. Greely, Breaking the Stalemate: A
ProspectiveRegulatory Frameworkfor Unforeseen Research Uses of Human Tissue Samples
and Health Information, 34 WAKEFoEST L. REv. 737 (1999).
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rights, pricing, and the availability of certain drugs in developing countries.10
Dr. Kaninda's appearance at Nova Southeastern University was important,
not simply because of her distinguished career, but also because of the
esteem with which others regard her employer. Doctors Without Borders/
M6decins Sans Fronti~res received the Nobel Peace Prize in 1999 for its
work in sending more than 2000 medical workers to provide care in nearly
ninety countries.
In addition to the articles from these distinguished visiting professors,
this issue of the Nova Law Review contains student articles on medical-legal
topics. Some of the students whose articles appear here-specifically,
Daniel Cohen, Judith Goodman, Jesse Lieberman and Stacy Warman-were
students in the Goodwin Seminar and benefited in their research and writing
from interaction with the Goodwin professors. Another, Sandy Martin, has
joined the Law Review since the Goodwin Seminar but undoubtedly also has
profited from the medical-legal knowledge Law Review editors gained
through the seminar. For all this, the NSU Law Center, and I in particular,
owe a special debt of gratitude to the Leo Goodwin Foundation, Inc. for its
generous support of the Goodwin Seminar and the Goodwin Chair in Law.
Finally, the reader should know that the seminar's health care theme
reflects the NSU Law Center's commitment to its health law curriculum and
programs. The NSU Law Center offers a health law concentration, providing law students the opportunity to specialize in either transactional or
litigation-related health law studies. In July 2001, it also began offering an
online master's degree in health law for non-lawyers, the first such program
to be offered by an ABA-accredited law school. Through the latter program,
the NSU Law Center intends to both help improve the health care system
and honor the American Bar Association's suggestion that law schools
educate non-lawyers about the law."
All of these efforts are linked. As the United States struggles with the
form of its health care system, and as the choices it makes during that struggle affect patient care, health care professionals, lawyers and the public, all
must become more conversant with health care policy issues. Legal decisions affecting health care cost, quality, and access in the new millennium
will determine the sort of care patients receive, not just here in United States
but also worldwide. This issue of the Nova Law Review, the 2001 Goodwin
10.

Anne-Valerie Kaninda, M.D., A Conversation with Dr.Anne-Valerie Kaninda, 26

NOVA L. REv. 451 (2002).

11.

See Philip S. Anderson, Learning to Educate the Public, A.B.A. J., July 1999, at
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Seminar, and the NSU Law Center's commitment to health law education
will help prepare both health care lawyers and members of the health care
industry to participate in decision making with regard to this important
subject.

Published by NSUWorks, 2002

5

